Wednesday, January 21, 2015

Top 10 Asian Stocks To Own Right Now

Blue-chip stocks were broadly higher today after a bevy of economic news lifted the spirits of analysts, investors, and traders. At close, the Dow Jones Industrial Average (DJINDICES: ^DJI  ) is up by 106 points, or 0.69%.

Stocks were primed to advance well before the markets opened for trading this morning. Yesterday, a member of the European Central Bank's executive board affirmed that the bank would continue with its accommodative monetary stance for as long as necessary. These comments were seconded today by a member of the Bank of Japan's board, who emphasized that it was vital for the East Asian country to keep interest rates both low and stable.

The news from both banks was met with particular relief this week after last week's comments by the U.S. Federal Reserve were interpreted to mean that it may soon reduce its monthly bond purchases, which have fueled equity gains. To read more about this, click here.

Beyond central banks, investors were also upbeat after learning about the improving mind-set of the American consumer. The Conference Board released the results of its most recent consumer sentiment survey today, showing that American's are more confident than they've been about the economy since 2008. The index climbed to 76.2 this month from a reading of 69 last month. The average economist surveyed by MarketWatch had predicted a reading of 72.3.

10 Best Airline Stocks To Invest In 2015: ImmunoGen Inc.(IMGN)

ImmunoGen, Inc. engages in the research and development of targeted therapeutics for the treatment of cancer using cancer biology, monoclonal antibodies, and highly potent cell-killing agents. The company develops its products using its Targeted Antibody Payload (TAP) technology. Its product candidates include Trastuzumab emtansine (T-DM1), a Phase III clinical trial product for HER2+ breast cancer; lorvotuzumab mertansine (IMGN901), a Phase I clinical trial product, which targets CD56 found on small-cell lung cancer, Merkel cell carcinoma, multiple myeloma, ovarian cancers, carcinoid tumors, and other cancers of neuroendocrine origin; IMGN529, a pre-investigational new drug stage drug for CD37+ B-cell malignancies, such as non-Hodgkin's lymphoma; and IMGN853, a preclinical stage product for cancers that overexpress folate receptor 1, including ovarian cancer. The company?s earlier-stage compounds in development stage comprise SAR3419, a Phase I clinical trial product for CD19+ B-cell malignancies, including non-Hodgkin's lymphoma; SAR650984, a Phase I clinical trial product for CD38+ hematological malignancies; SAR566658, a phase one clinical trial product for DS6+ solid tumors; and BT-062, a Phase I product for multiple myeloma. It has collaboration agreements with Amgen, Inc.; Bayer Schering Pharma AG; Biogen Idec MA Inc.; Biotest AG; Genentech, Inc.; Novartis Institutes for BioMedical Research, Inc.; and sanofi-aventis U.S. LLC. ImmunoGen, Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts.

Advisors' Opinion:
  • [By Sean Williams]

    A moat of competition, but plenty of upside
    However, investors would probably be wise not to get too carried away with yesterday's news given that another therapy -- which I would certainly call revolutionary�-- known as Kadcyla for HER2-positive breast cancer was just approved in February. Kadcyla, developed by Roche�and ImmunoGen (NASDAQ: IMGN  ) piggybacks a toxin on an antibody and, using ImmunoGen's proprietary targeted antibody payload technology, delivers a higher dose of toxin directly to the targeted cancer, which has a signature protein that causes the release of the toxin from the antibody. In late-stage trials, Kadcyla improved PFS by 50% over the placebo to 9.6 months.

  • [By Lee Jackson]

    While very upbeat on the sector as a whole, UBS was very cautious on sell-rated Ironwood Pharmaceuticals, Inc (NASDAQ: IRWD) and ImmunoGen Inc. (NASDAQ: IMGN). Neutral-rated Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) and Seattle Genetics Inc. (NASDAQ: SGEN) were also viewed with a skeptical eye.

  • [By John Udovich]

    Cramer Talks Up Biotech and Cancer Biotech in Particular. For what his opinion might be worth, MSNBC�� Mad Money host Jim Cramer recently commented that the 25 best-performing small cap stocks this year are "almost entirely biotech." He went on to point out that Celldex Therapeutics has been "just incredible��and that other companies to watch include Celgene Corporation (NASDAQ: CELG), ImmunoGen, Inc (NASDAQ: IMGN) and Onyx Pharmaceuticals, Inc (NASDAQ: ONXX), which all have promising cancer products on the way. He also added that:�

  • [By Sean Williams]

    A new type of treatment that involves utilizing antibodies to carry toxins also shows plenty of promise. These antibodies work by releasing a toxin once they come into contact with very specific protein signatures released by the targeted cancer cells, and could be the key to targeted cancer treatments. One example is Roche and ImmunoGen's (NASDAQ: IMGN  ) Kadcyla, which was approved by the FDA in February as a second-line treatment for HER2-positive breast cancer. The drug combines the HER2 protein-blocking power of Herceptin and uses ImmunoGen's targeted antibody payload technology to deliver the chemotherapy agent directly to the cancer cells. With minimal healthy tissue death, Kadcyla improved progression-free survival and median overall survival by 3.2 months and 5.8 months, respectively, as compared to another current standard of treatment, which is GlaxoSmithKline's�and Roche's Xeloda.

Top 10 Asian Stocks To Own Right Now: Genel Energy PLC (GEGYF.PK)

Genel Energy plc, formerly Vallares PLC, is an exploration and production company. It is an independent oil producer in the Kurdistan Region of Iraq. The Group has two reportable business segments, which are its oil and gas exploration and production business in the KRI and its oil and gas exploration business in Africa. The Company had operational bases in Ankara, Turkey; in Taq Taq, Erbil and Suleimaniah in the Kurdistan Region, and in London. The Company�� oil producing fields of Taq Taq (in which it held a 44% interest) and Tawke (25% interest) had estimated gross proven and probable reserves of 1.2 billion barrels of oil and proven, probable and possible reserves of 1.9 billion barrels of oil. The Company�� subsidiaries include: Genel Energy Holding Company Ltd, Genel Energy Somaliland Limited, A&T Petroleum Limited, Genel Energy UK Services Limited, Genel Energy Netherlands Holding 2 B.V. and Genel Energy Somaliland Limited. Advisors' Opinion:
  • [By Street Smart Investor]

    DNO International is an independent E&P company, geographically focused on the Middle East and North Africa with operations in Yemen, the Kurdistan region of Iraq, Tunisia, Oman, Ras Al Khaimah and Somaliland. The company's asset portfolio currently stands at 20 assets in six countries. For the year ended December 2012, DNO International has proven and probable reserves of 520.3 MMboe with 90% of the reserves in the Kurdistan region of Iraq. The company's reserves in Kurdistan come from the Tawke oil block, which is among the largest oil blocks in Kurdistan. DNO International has a 55% stake in the Tawke block with Genel Energy PLC (GEGYF.PK) holding a 25% stake. The remaining 20% stake is held by the Kurdistan Regional Government. For the first half of 2013, DNO International had a production rate of 33,917 boepd, which includes production from Kurdistan, Oman and Yemen.

Top 10 Asian Stocks To Own Right Now: Dassault Systemes SA (DSY)

Dassault Systemes SA provides software solutions and consulting services. The Company�� global customer base includes companies primarily in 11 industrial sectors: Aerospace & Defense, Transportation & Mobility, Marine & Offshore, Industrial Equipment, High Tech, Architecture, Engineering & Construction, Consumer Goods Retail, Consumer Packaged goods Retail, Life Sciences, Energy, Process & Utilities, Financial & Business services. To serve these industries, the Company has developed a broad software applications portfolio, organized in brands, in order to provide comprehensive solutions responding to the extensive requirements of product development: Design, Realistic Simulation, Virtual Manufacturing and Production, Collaborative Innovation, Lifelike Experiences and Information Intelligence. In July 2013, it acquired Apriso. In September 2013, it acquired Safe Technology Ltd. In January 2014, the Company acquired 84% interest in Realtime Technology AG. Advisors' Opinion:
  • [By Julia Leite]

    The FTSE/JSE Africa All Shares Index fell 1.8 percent, the most since July 5. Discovery Ltd. (DSY), South Africa�� largest medical-insurance provider, sank 9.1 percent after saying profit will be as much as 10 percent lower than the previous period.

Top 10 Asian Stocks To Own Right Now: Mcdermott International Inc (MDR)

McDermott International, Inc. (MII),incorporated on August 11, 1959, is a engineering, procurement, construction and installation (EPCI) company. The Company is focused on designing and executing complex offshore oil and gas projects worldwide.

The Company provides fully integrated EPCI services; it delivers fixed and floating production facilities, pipeline installations and subsea systems from concept to commissioning. Its business segments consist of Asia Pacific, Atlantic, Caspian and the Middle East. On March 19, 2012, the Company completed the sale of its former charter fleet business, which operated 10 of the 14 vessels.

Asia Pacific Segment

Through the Company�� Asia Pacific segment, it serves the needs of customers primarily in Australia, Indonesia, Vietnam, Malaysia and Thailand. Project focus in this segment includes the fabrication and installation of fixed and floating structures and the installation of pipelines and subsea systems. The majority of its projects in this segment are performed on an EPCI basis. Engineering and procurement services are provided by its Singapore office and are supported by additional resources located in Chennai, India and Houston, Texas. The primary fabrication facility for this segment is located on Batam Island, Indonesia. Additionally, through its equity ownership interest in a joint venture, the Company has developed a fabrication facility located in China.

The Company competes with Allseas Marine Contractors S.A.; Daewoo Engineering & Construction Co., Ltd.; EMAS Offshore Pte Ltd.; Heerema Group; Hyundai Heavy Industrial Co., Ltd.; Nippon Steel Corporation; Saipem S.P.A.; Samsung Heavy Industries Co., Ltd.; Sapura Kencana Petroleum; Subsea 7 S.A.; Swiber Holdings Ltd., and Technip S.A.

Atlantic Segment

Through the Company�� Atlantic segment, it serves the needs of customers primarily in the United States, Brazil, Mexico, Trinidad and West Africa. Project focus in this s! egment includes the fabrication and installation of fixed and floating structures and the installation of pipelines and subsea systems. Engineering and procurement services are provided by its Houston office, and its New Orleans office provides marine engineering capabilities to support its global marine activities. The primary fabrication facilities for this segment are located in Morgan City, Louisiana and Altamira, Mexico.

The Company competes with Allseas Marine Contractors S.A.; Dragados Offshore Mexico, S.A.; Gulf Island Fabrication Inc.; Heerema Group; Helix Energy Solutions Group, Inc.; KBR, Inc.; Kiewit Corporation; Saipem S.P.A.; Subsea 7 S.A., and Technip S.A.

Middle East Segment

Through the Company�� Middle East segment, which includes the Caspian region, it serves the needs of customers primarily in Saudi Arabia, Qatar, the United Arab Emirates (U.A.E.), Kuwait, India, Azerbaijan, Russia, and the North Sea. Project focus in this segment relates primarily to the fabrication and offshore installation of fixed and floating structures and the installation of pipelines and subsea systems. The majority of its projects in this segment are performed on an EPCI basis. Engineering and procurement services are provided by its Dubai, U.A.E., Chennai, India and Al Khobar, Saudi Arabia offices and are supported by additional resources from its Houston and Baku, Azerbaijan offices. The primary fabrication facility for this segment is located in Dubai, U.A.E.

The fabrication facilities in each segment are equipped with a variety of heavy-duty construction and fabrication equipment, including cranes, welding equipment, machine tools and robotic and other automated equipment. Project installation is performed by construction vessels, which the Company owns or leases and are stationed throughout the various regions and provide structural lifting/lowering and pipelay services. These construction vessels are supported by its multi-function vessels and chart! ered vess! els from third parties to perform a wide array of installation activities that include anchor handling, pipelay, cable/umbilical lay, dive support and hookup/commissioning.

The Company competes with Hyundai Heavy Industrial Co. Ltd.; Keppel Corporation; Larsen and Toubro Ltd (India); National Petroleum Construction Company (Abu Dhabi); Saipem S.P.A.; Technip S.A.; and Valentine and Swiber Holdings Ltd.

Advisors' Opinion:
  • [By Roberto Pedone]

    One under-$10 engineering player that's trending very close to triggering a big breakout trade is McDermott International (MDR), an engineering, procurement, construction and installation company engaged on designing and executing complex offshore oil and gas projects. This stock has been hit hard by the bears so far in 2013, with shares off by 31%.

    If you take a look at the chart for MDR, you'll notice that this stock recently gapped down sharply from close to $9 a share to its recent low of $6.68 a share with heavy downside volume. Following that move, shares of MDR have started to rebound off that $6.68 low, and the stock is now starting to move within range of triggering a major breakout trade.

    Traders should now look for long-biased trades in MDR if it manages to break out above some near-term overhead resistance at $7.74 a share with high volume. Look for a sustained move or close above that level with volume that hits near or above its three-month average action of 4.33 million shares. If that breakout triggers soon, then MDR will set up to re-fill some of its previous gap down zone from August that started near $9 a share. If MDR gets into that gap with volume, then this stock could easily hit $9 to $10 a share.

    Traders can look to buy MDR off weakness to anticipate that breakout and simply use a stop that sits right below some near-term support levels at $7.04 o around its recent low of $6.68 a share. One can also buy MDR off strength once it takes out $7.74 a share with volume and then simply use a stop that sits a comfortable percentage from your entry point.

  • [By Jake L'Ecuyer]

    Equities Trading DOWN
    Shares of McDermott International (NYSE: MDR) were down 6.97 percent to $7.55 after the company reported a Q4 loss of $1.37 per share on revenue of $517.3 million. It also withdrew its previous outlook. Capital One Financial downgraded the stock from Equalweight to Underweight and cut the price target from $8.00 to $6.00.

  • [By Sean Williams]

    Digging the chance for a rebound
    If you've been keeping your eye on the oil and gas drilling sector lately, you'd be hard pressed to find poorly performing companies, but offshore services company McDermott International (NYSE: MDR  ) is one of the few that fits the bill.

  • [By Brian Pacampara]

    Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, engineering and construction company McDermott International (NYSE: MDR  ) has earned a coveted five-star ranking.

Top 10 Asian Stocks To Own Right Now: Volcano Corporation(VOLC)

Volcano Corporation designs, develops, manufactures, and commercializes intravascular ultrasound (IVUS) and fractional flow reserve (FFR) products used in the diagnosis and treatment of vascular and structural heart disease. It offers multi-modality consoles, which are marketed as stand-alone units that can be integrated into hospital-based interventional surgical suites, such as catheterization laboratories. The company provides IVUS products, including single-procedure disposable phased array and rotational IVUS imaging catheters; and additional functionality options comprising virtual histology tissue characterization, and ChromaFlo stent apposition analysis. It also offers FFR products, such as pressure and flow consoles, and single-procedure disposable pressure and flow guide wires used to measure the pressure and flow characteristics of blood around plaque enabling physicians to gauge the plaque?s physiological impact on blood flow and pressure. In addition, the com pany develops and manufactures optical monitors for the telecommunication industry; laser and non-laser light sources; optical engines used in the medical OCT imaging systems and advanced photonic components; and sub-systems used in spectroscopy and other industrial applications. Its products under development include image-guided therapy device and micro and thrombectomy catheters. The company?s ongoing clinical studies comprise assessment of dual anti-platelet therapy with drug-eluting stents; vascular evaluation for revascularization; fractional flow reserve and intravascular ultrasound relationship study; adensonine vasodilation independent stenosis evaluation; and evaluation of XIENCE PRIME. It sells its products through direct sales force and distributors, as well as through third parties supply and distribution agreements primarily in the United States, Japan, Europe, the Middle East, Africa, and internationally. The company was founded in 2000 and is headquartered i n San Diego, California.

Advisors' Opinion:
  • [By Ali Berri]

    Volcano (NASDAQ: VOLC) shares tumbled 19.58 percent to $12.69 on Q2 results. The company reported Q2 earnings of $0.01 per share on revenue of $102.60 million. Volcano announced its plans to divest its Axsun Technologies subsidiary and also announced the litigation settlement agreement with St. Jude Medical (NYSE: STJ). Oppenheimer downgraded Volcano from Outperform to Market Perform and lowered the price target from $22.00 to $15.00.

Top 10 Asian Stocks To Own Right Now: Cytomedix Inc (CMXI)

Cytomedix, Inc. (Cytomedix), incorporated in April 29, 1998, is a regenerative therapies company marketing and developing products within the United States and internationally .The Company commercializes cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing. The Company is a commercial operation, and a robust clinical pipeline representing a logical extension of its commercial technologies in the evolving field of regenerative medicine. Cytomedix primarily operates in the United States. Its commercial offerings are centered on its point of care platform technologies for the safe and efficient separation of blood and bone marrow to produce platelet based therapies or cell concentrates.

The Company markets and selsl two distinct platelet rich plasma (PRP) technologies, the AutoloGel System for wound care and the Angel concentrated Platelet Rich Plasma (cPRP) Sytem in orthopedic and cardiovascular markets. Its clinical pipeline includes the ALDH, which are cell-based therapies (Bright Cells). In February 2012, the Company acquired Aldagen, Inc.

The AutoloGel System

The AutoloGel System is a point of care device for the production of a platelet based bioactive therapy derived from a small sample of the patient�� own blood. Using the patient�� own platelets as a therapeutic agent, AutoloGel harnesses the body�� natural healing processes to deliver growth factors, chemokines and cytokines known to promote angiogenesis and to regulate cell growth and the formation of new tissue.

Angel Product Line

The Angel concentrated Platelet Rich Plasma (cPRP) System is a multi-functional cell separation device which produces concentrated platelet rich plasma for use in the operating room and clinic and is used in a range of orthopedic and cardiovascular indications. Similar to the AutoloGel System, the Angel System is a point of care device for the production of a concentrated, aseptic platelet! -based bioactive therapy derived from a small sample of the patient�� own blood. The resulting cPRP is applied at the site of injury to promote healing. The Angel product line also includes ancillary products such as phlebotomy and applicator supplies and activAT. activAT is designed to produce autologous thrombin serum from platelet poor plasma and is sold exclusively in Europe and Canada, where it provides a safe alternative to bovine-derived products.

ALDHbr Cell Technology and Development Pipeline

The ALDHbr (Bright Cell) technology is an approach to cell-based regenerative medicine and a logical extension of its commercial technologies in the evolving regenerative medicine market, with potential clinical indications in markets with unmet medical needs such as peripheral arterial disease and ischemic stroke. The Bright Cell technology is in that it utilizes an intracellular enzyme marker to facilitate fractionation of essential regenerative cells from a patient�� bone marrow. The bone marrow fractionation process identifies and isolates active stem and progenitor cells expressing high levels of the enzyme aldehyde dehydrogenase, or ALDH, which is a key enzyme involved in the regulation of gene activities associated with cell proliferation and differentiation.

The Company�� lead product candidate, ALD-401, is an autologous preparation of Bright Cells for the post-acute treatment of ischemic stroke. ALD-401 is being evaluated in the RECOVER-Stroke clinical study, an ongoing 100-patient, double-blind, placebo-controlled Phase 2 study in patients with unilateral, cerebral ischemic stroke with an NIH stroke scale score of less than 22. An additional product candidate, ALD-301, is in clinical development for peripheral arterial disease (PAD), a condition causing reduced flow of blood and oxygen to muscles in the leg. It has completed a Phase 1/2 study of autologous ALD-301 in critical limb ischemia (CLI), a late stage condition caused by PAD. The Phase 2 PACE! (Patient! s with Intermittent Claudication Injected with ALDH Bright Cells) study is an 80 patient, double-blind, placebo-controlled clinical trial intended to demonstrate the safety and efficacy of ALD-301 (Bright Cells) in patients diagnosed with IC.

The Company competes with Harvest Technologies (a subsidiary of Terumo), Biomet, Arteriocyte, and Arthrex.

Advisors' Opinion:
  • [By James E. Brumley]

    To give credit where it's due, Cytomedix, Inc. (OTCBB:CMXI) and Baxter International Inc. (NYSE:BAX) have both helped shape the landscape of the hemostasis (bleeding control) market with their products, AutoloGel and TISSELL, respectively. Arch Therapeutics Inc. (OTCBB:ARTH) has proverbially taken their concepts "up a notch", however, and its direct solution to a problem that CMXI and BAX can't quite solve may make ARTH the hottest trading candidate in the hemostasis space.

Top 10 Asian Stocks To Own Right Now: Verint Systems Inc (VRNT)

Verint Systems Inc. (Verint), incorporated in February 1994, is engaged in Actionable Intelligence solutions and value-added services. More than 10,000 organizations use Verint Actionable Intelligence solutions to capture, distill, and analyze complex and underused information sources, such as voice, video, and unstructured text. In the security intelligence market, it offers communications and cyber intelligence, video and situation intelligence, and public safety solutions help government and commercial organizations to protect people and property. On March 30, 2011, the Company acquired Rontal Engineering Applications Ltd. On August 2, 2011, the Company acquired a privately held provider of communications intelligence solutions, data retention services, and network performance management, based in the Americas region. On August 4, 2011, the Company acquired Vovici Corporation (Vovici). On October 7, 2011, the completed the acquisition of Global Management Technologies (GMT). On November 1, 2011, the Company acquired certain technology and other assets for use in its Communications Intelligence operating segment. On November 10, 2011, the Company acquired certain technology and other assets for use in its Enterprise Intelligence operating segment in a transaction. On January 5, 2012, the Company acquired a privately held provider of Web intelligence technology, based in the Americas, Europe, the Middle East, and Africa (EMEA) region. In February 2014, Verint Systems Inc has completed its acquisition of KANA Software, Inc, a portfolio company of Accel-KKR.

The Enterprise Intelligence Solutions Segment

The Company is a provider of enterprise intelligence software and services. Its solutions enable organizations to extract and analyze information from customer interactions and related operational data. It markets these solutions under the Impact 360 brand to contact center, back-office, and branch and remote office operations, to other customer-facing departments, such as sale! s and marketing. These solutions comprise a range of enterprise workforce optimization and voice of the customer solutions and services, which include Internet protocol (IP) and Time Division Multiplexing (TDM) voice recording, quality monitoring, voice of the customer analytics (speech, text, and enterprise feedback management), workforce management, e-Learning and coaching, performance management, and desktop and process analytics. These solutions can be deployed stand-alone or in an integrated fashion.

The Company�� Impact 360 is an unified portfolio of workforce optimization and voice of the customer solutions. Its portfolio of Enterprise Intelligence Solutions include Quality Monitoring, Full-Time and Compliance Recording, Workforce Management, Voice of the Customer Analytics (Speech, Text, and Enterprise Feedback Management), Performance Management, e-Learning and Coaching, Desktop and Process Analytics, Workforce Optimization and Voice of the Customer for Small-to-Medium Sized Businesses and Public Safety. Quality Monitoring records multimedia interactions based on user-defined business rules and provides interaction assessment functionality, including intelligent evaluation forms and automatic delivery of calls for evaluation according to quotas or contact-related criteria. Its Full-Time and Compliance Recording provides contact center recording for compliance, sales verification, and monitoring in IP, traditional TDM, and mixed telephony environments. It includes encryption capabilities to help support the payment card industry data security standard and other regulatory requirements for protecting sensitive data. Workforce Management Helps enterprises forecast staffing requirements, deploy the appropriate level of resources, and evaluate the productivity of their customer service staff. It also includes optional strategic planning capabilities. Its speech analytics solutions analyze call content for the purpose of identifying business trends, building containment and customer s! ervice st! rategies, and quality monitoring programs. Its text analytics analyze structured and unstructured data in multiple text sources include e-mail, chat sessions, blogs, contact center notes, white mail, survey comments, and social media channels. Its enterprise feedback management solutions provide enterprise-wide customer feedback capabilities through surveys and online communities to centralize and simplify survey management, deployment, and analysis across survey platforms, including interactive voice response, e-mail, social media, and mobile devices. Performance Management Provides a view of key performance indicators (KPIs), with performance scorecards and reports on customer interactions, customer experience trends, and contact center, back-office, branch, remote office, and customer service staff performance. e-Learning and Coaching Enables enterprises to deliver Web-based training to customer service staff desktops, including learning clips created from recordings and other customized materials to staff needs and competencies. Desktop and Process Analytics Captures information from customer service employee interactions with their desktop applications to provide insights into productivity, training issues, process adherence, and bottlenecks. Workforce Optimization and Voice of the Customer for Small-to-Medium Sized Businesses is designed for smaller companies (with contact centers), which face the same business requirements as their larger competitors. Public Safety includes quality assurance, forecasting and scheduling, speech analytics, performance scorecards, citizen surveys, incident investigation and analytics, and full-time and compliance recording solutions under the brand Impact 360 for Public Safety Powered by Audiolog. Its public safety solution allows first responders (police, fire departments, emergency medical services, etc.) in the security intelligence market to deploy workforce optimization solutions to record, manage, and act on incoming assistance requests and related data.

! The Company competes with Aspect Software, Inc., HP company, Genesys Telecommunications, NICE Systems Ltd. (NICE).

The Video and Situation Intelligence Solutions Segment

The Company is a provider of networked IP video solutions and a provider of situation intelligence solutions to optimize security and enhance operations. Its solutions, marketed under the Nextiva brand, include IP video management software and services, edge devices for capturing, digitizing, and transmitting video over different types of wired and wireless networks, video analytics, network video recorders, and physical security information management. Its networked IP video portfolio enables organizations to deploy an end-to-end IP video solution with analytics or evolve to IP video solutions. Its situation intelligence solutions enable organizations to view, correlate, and analyze information from various stand-alone systems and sensors. It is engaged in the networked IP video market with Nextiva, an end-to-end, networked IP video solution portfolio. Its IP Video Management Software simplifies management of video and geographically dispersed video surveillance operations, with a suite of applications, which includes automated system health monitoring, policy-based video distribution, networked video viewing, and investigation management. It is designed for use with industry-standard servers and storage solutions and for interoperability with other enterprise systems. Edge Devices captures, digitizes, and transmits video across enterprise networks. It includes IP cameras, bandwidth-efficient video encoders to convert analog images to IP video for transmission over IP networks, and wireless devices, which perform both video encoding and wireless IP transmission. Video Analytics Analyzes video content to detect anomalies and activities of interest, such as perimeter intrusion, unattended objects, camera tampering, and vehicles moving in the wrong direction. It also includes industry-specific analytics applicati! ons. Netw! ork Video Recorders Performs networked video recording utilizing secure, embedded operating systems and market-specific data integrations for applications, which require local storage, as well as remote networking.

The Company�� Physical Security Information Management (Situation Intelligence) captures and integrates information from various stand-alone security and public safety systems, such as access control, video, intrusion, fire and public safety, first responder, and other mobile device systems. Its Video Intelligence solutions are deployed across a range of industries, including banking, retail, critical infrastructure, government, corporate campuses, education, airports, seaports, public transportation, and homeland security. Its video solutions include video analytics and data integrations.

The Company competes with 3VR, Tyco, Genetec Inc., March Networks Corporation, Milestone Systems A/S, NICE and Schneider Electric Limited.

The Communications and Cyber Intelligence Solutions Segment

The Company is a provider of communications intelligence solutions and a developer of cyber intelligence solutions, which help law enforcement, national security, intelligence, and civilian government agencies detect, investigate, and neutralize criminal and terrorist threats and detect and thwart cyber-attacks. Its portfolio includes solutions for communications interception, service provider compliance, mobile location tracking, open source Web intelligence, cyber intelligence and tactical communications intelligence. These solutions can be deployed stand-alone or collectively. The Company is engaged in the market for communications intelligence solutions and a developer of cyber intelligence solutions, which are marketed under the RELIANT, VANTAGE, STAR-GATE, ENGAGE, FOCALINFO, and CYBERVISION brand names. Its Communications Interception enables the interception, monitoring, and analysis of information collected from a range of communications networks, inc! luding fi! xed and mobile networks, IP networks, and the Internet. It includes lawful interception solutions designed to intercept specific target communications pursuant to legal warrants and mass interception solutions for investigating and proactively addressing criminal and terrorist threats. Communications Service Provider Compliance enables communication service providers to collect and deliver to government agencies specific call-related and call-content information in compliance with Communications Assistance for Law Enforcement Act (CALEA), European Telecommunications Standards Institute (ETSI), and other compliance regulations and standards. It includes a scalable warrant and subpoena management system. Its Mobile Location Tracking tracks the location of mobile network devices for intelligence and evidence gathering, with analytics and workflow designed to support investigative activities. It provides real-time tracking of multiple targets, real-time alerts, and investigative capabilities, such as geospatial fencing and events correlation. Its Open Source Web Intelligence features advanced data collection, text analysis, data enrichment and analytics. Tactical Communications Intelligence provides portable communications interception and location tracking capabilities for local use or integration with centralized monitoring systems, to support tactical field operations. Its Cyber Intelligence designed to provide network-based cyber security, including malware detection capabilities for high-speed networks, for national cyber protection organizations.

The Company competes with Bosch Security Systems, Cisco Systems, Inc., United Technologies Corp., Honeywell International Inc., Aqsacom Inc., BAE Systems, JSI Telecom, NICE, Pen-Link, Ltd., RCS S.R.L., Rohde & Schwarz, Trovicor, SS8 Networks, Inc. and Sophos, Plc.

Advisors' Opinion:
  • [By Lisa Levin]

    Verint Systems (NASDAQ: VRNT) shares rose 3.88% to $48.75. The volume of Verint Systems shares traded was 881% higher than normal. Verint reported better-than-expected fourth-quarter results and issued a strong full-year forecast. Verint reported its adjusted earnings of $0.91 per share on revenue of $257.1 million.

  • [By Lee Jackson]

    Verint Systems Inc. (NASDAQ: VRNT) is a global leader in actionable intelligence solutions. Its portfolio of Enterprise Intelligence Solutions and Security Intelligence Solutions helps organizations make Big Data actionable through the ability to capture, analyze and act on large volumes of rich, complex and often underused information sources — such as voice, video and unstructured text. With Verint solutions and value-added services, organizations of all sizes can make more timely and effective decisions. More than 10,000 organizations in over 150 countries, including more than 80% of the Fortune 100, count on Verint solutions to improve enterprise performance. The J.P. Morgan price target is $51, and consensus estimate is inline at $51.29. Verint closed Tuesday at $47.12.

  • [By Tess Stynes]

    Verint Systems Inc.(VRNT) agreed to buy customer-service software firm Kana Software Inc.(SWKH) from private equity firm Accel-KKR for about $514 million in cash, as the data-analysis company seeks to expand its offerings.

  • [By shash63]

    In January, Nice Systems (NICE) had announced that it is in discussion with Verint Systems (VRNT) for possible acquisition. This acquisition will cost Nice Systems $1.5 billion. After this acquisition, the combined sales of both companies is expected to be around $1.5 billion annually, and it will control 70% of the voice recording market, and 50% of the video recording market. This acquisition shouldn�� face any hurdles as Verint System recently purchased the controlling stake of its holding company, Comverse Technologies, thus becoming an independent company. This deal will make it simpler for Nice System to acquire Verint Systems.

No comments:

Post a Comment